BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Subscribe To Our Newsletter & Stay Updated